secwatch / observer
8-K filed March 5, 2024, 6:59 PM ET CIK 0001522860
debt confidence high sentiment negative materiality 0.65

Acutus Medical waives default from Biotronik arbitration; amends credit to allow delisting, $3M exposure trigger

Acutus Medical, Inc.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Acutus Medical, Inc. amended Waiver and Amendment No. 3 to Amended and Restated Credit Agreement and Amendment to Lender Warrants and Warrant Purchase Agreement with Deerfield Partners, L.P. and Deerfield Private Design Fund III, L.P. (effective 2024-03-04).

Action
amendment
Agreement
credit facility
Counterparty
Deerfield Partners, L.P. and Deerfield Private Design Fund III, L.P.
Effective
2024-03-04
Exact text from the filing
On March 4, 2024, Acutus Medical, Inc. (the “Company”) and Deerfield Partners, L.P. and Deerfield Private Design Fund III, L.P. (collectively, the “Lenders”) entered into the Waiver and Amendment No. 3 to Amended and Restated Credit Agreement and Amendment to Lender Warrants and Warrant Purchase Agreement (the “Amendment”) to amend (i) the Amended and Restated Credit Agreement, dated as of June 30, 2022 (as amended, restated, supplemented or otherwise modified from time to time, the “Credit Agreement”), among the Company, the Lenders from time to time party thereto and Wilmington Trust, National Association, as the Administrative Agent, (ii) warrants to purchase the Company’s common stock (the “Lender Warrants”) issued to each Lender on June 30, 2022 and (iii) the Warrant Purchase Agreement, dated as of June 30, 2022, by and among the Company and the Lenders pursuant to which the Lender Warrants were issued (the “Warrant Purchase Agreement”).
View on SEC.gov

737 material agreements filed in the last 30 days. Browse all material agreements →

Source: SEC EDGAR
accession 0000950103-24-003398
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.